Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to email@example.com so that we can defer those challenges. Your health and safety are paramount to us.
Posted 08 March 2013 | By Louise Zornoza,
China's Ministry of Health and the State Food and Drug Administration (SFDA) have proposed draft regulations governing stem cell clinical trial management and the quality control of stem cell preparations and pre-clinical research.
All proposed clinical trials on stem cells would be subject to prior review by ethics committees, and sponsors would be required to submit informed consent forms, safety evaluation and research protocols as well as information concerning the qualifications of the principal investigators.
Sponsors would also have to submit information concerning the production of the investigational stem cell products. Moreover, only hospitals certified by the SFDA would be allowed to be sites for such trials. Also according to the rules, during the first three phases of stem cell clinical experiments, test subjects should not be charged. Medical institutions that violate the rules will lose their qualification and face penalties.
Tags: IRBs, Clinical Research, stem cells, clinical trials
Regulatory Focus newsletters
All the biggest regulatory news and happenings.